No headlines found.
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
Globe Newswire (Wed, 2-Apr 8:30 AM ET)
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 12-Mar 4:02 PM ET)
Alpha Tau to Participate in March Investor Conferences
Globe Newswire (Thu, 27-Feb 9:00 AM ET)
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
Globe Newswire (Mon, 24-Feb 8:30 AM ET)
Globe Newswire (Mon, 3-Feb 8:30 AM ET)
Globe Newswire (Mon, 27-Jan 9:00 AM ET)
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
Alpha Tau Medical Ltd. - trades on the NASDAQ stock market under the symbol DRTS.
As of April 11, 2025, DRTS stock price climbed to $2.55 with 4,241 million shares trading.
DRTS has a beta of 0.82, meaning it tends to be less sensitive to market movements. DRTS has a correlation of 0.07 to the broad based SPY ETF.
DRTS has a market cap of $178.76 million. This is considered a Micro Cap stock.
In the last 3 years, DRTS traded as high as $12.50 and as low as $1.75.
DRTS has underperformed the market in the last year with a return of -10.8%, while the SPY ETF gained +4.5%. In the last 3 month period, DRTS fell short of the market, returning -21.1%, while SPY returned -7.7%. However, in the most recent 2 weeks DRTS has outperformed the stock market by returning -0.4%, while SPY returned -3.9%.
DRTS support price is $2.39 and resistance is $2.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRTS shares will trade within this expected range on the day.